US Patent

US10093663 — Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof

Method of Use · Assigned to Novartis AG · Expires 2034-07-14 · 8y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a compound called IPTACOPAN HYDROCHLORIDE and its therapeutic uses, as well as methods for manufacturing it and related pharmaceutical compositions.

USPTO Abstract

The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4161`	—	iptacopan-hydrochloride

Patent Metadata

Patent number: US10093663
Jurisdiction: US
Classification: Method of Use
Expires: 2034-07-14
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.